Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda, US Biotech NsGene Team Up on Cell Encapsulation Therapies for Parkinson’s
January 12, 2016
- Otsuka Files Leukemia Drug Ponatinib in Japan
January 12, 2016
- Lilly Japan, Torii Link Up to Copromote Psoriasis Drug Ixekizumab
January 12, 2016
- Astellas, Boehringer Extend Copromotion Pact for Micardis
January 8, 2016
- Sanofi Launches Japan PIII on Vaccine for C. Diff Infection
January 8, 2016
- Nippon Shinyaku Files Japan NDA for PAH Drug Selexipag
January 8, 2016
- Toray Enters Field of Nucleic Acid Medicine through Tie-Up with Bonac
January 8, 2016
- Belsomra Most Heavily Pitched Drug in November: Anterio
January 7, 2016
- Novartis, Chugai to Close Out Comarketing Scheme for Femara
January 7, 2016
- Takeda, French Startup Tie Up on Gut Bacteria-Derived Drugs for GI Disorders
January 7, 2016
- Selexipag Now Available in US: Nippon Shinyaku
January 6, 2016
- Generic Use Rate at 54.7% in July-September 2015: JGA
January 6, 2016
- Fuji Pharma Licenses Nesp Biosimilar from S. Korean Firm
January 6, 2016
- Blopress, Takepron to Go to Teva-Takeda Joint Venture
January 5, 2016
- Torii Files NDA for Allergen Immunotherapy Tablet for Cedar Pollinosis
January 5, 2016
- ASKA Files Rifaximin for Hepatic Encephalopathy
December 25, 2015
- Bristol-Myers Files Elotuzumab for Relapsed, Refractory Multiple Myeloma in Japan
December 25, 2015
- FDA OKs Selexipag Originated by Nippon Shinyaku
December 24, 2015
- MSD Seeks Japan Approval for Pembrolizumab for Melanoma
December 24, 2015
- Israel’s Pluristem Therapeutics to Enter into Japanese Regenerative Medicine Market
December 24, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…